Literature DB >> 7082534

Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis.

R E Bullingham, H J McQuay, E J Porter, M C Allen, R A Moore.   

Abstract

1 A 10 h study of plasma drug concentrations of the opiate buprenorphine after use was designed because a previous 3 h study had shown that peak plasma drug concentrations in some patients had not occurred by 3 h after the sublingual dose. 2 Fifteen postoperative patients were studied: at 3 h after a 0.3 mg intravenous dose five patients received a sublingual preparation of 0.4 mg of buprenorphine, five 0.8 mg of buprenorphine and five placebo. Plasma drug concentrations of buprenorphine were measured by specific radioimmuno-assay. 3 Plasma drug concentrations after sublingual buprenorphine were significantly higher than those in the placebo group by 1 h. They remained significantly higher over the succeeding nine hours. The mean time to peak plasma drug concentration was about 200 min in both the 0.4 mg and 0.8 mg groups (range 90-360 min). The plasma drug concentrations in the 0.8 mg group were approximately twice those in the 0.4 mg group; the ratio of the relative systemic availabilities was similarly 1.8:1. The absolute systemic availability was estimated at about 55% for both groups. Uptake of buprenorphine from the sublingual site was essentially complete by 5 h after the dose was given. 4 The implications for the timing of sublingual doses in clinical use are discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7082534      PMCID: PMC1402077          DOI: 10.1111/j.1365-2125.1982.tb01434.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

2.  A new buccal absorption model.

Authors:  J C Dearden; E Tomlinson
Journal:  J Pharm Pharmacol       Date:  1971-12       Impact factor: 3.765

3.  Analysis of human buccal absorption of drugs by physical model approach.

Authors:  K R Vora; W I Higuchi; N F Ho
Journal:  J Pharm Sci       Date:  1972-11       Impact factor: 3.534

4.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man.

Authors:  J G Wagner
Journal:  J Theor Biol       Date:  1968-08       Impact factor: 2.691

5.  A comparison of the physico-chemical properties and potency of pethidine and phenoperidine [proceedings].

Authors:  K Chan; G R Murray; G C Ong
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

6.  Analgesic effects of sublingual buprenorphine.

Authors:  W G Edge; G M Cooper; M Morgan
Journal:  Anaesthesia       Date:  1979-05       Impact factor: 6.955

7.  Relief of pain after surgery. A comparison of sublingual buprenorphine and intramuscular papaveretum.

Authors:  E N Fry
Journal:  Anaesthesia       Date:  1979-06       Impact factor: 6.955

8.  Absorption of analgesics from the buccal mucous membrane.

Authors:  A S Brown
Journal:  Practitioner       Date:  1966-01

Review 9.  Clinical use of nicotine chewing-gum.

Authors:  M A Russell; M Raw; M J Jarvis
Journal:  Br Med J       Date:  1980-06-28

10.  Buprenorphine kinetics.

Authors:  R E Bullingham; H J McQuay; A Moore; M R Bennett
Journal:  Clin Pharmacol Ther       Date:  1980-11       Impact factor: 6.875

View more
  32 in total

Review 1.  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Authors:  Alexander Elkader; Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of drug administered buccally and sublingually.

Authors:  J G Motwani; B J Lipworth
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

Review 3.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

4.  Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.

Authors:  Chee M Ng; Erin Dombrowsky; Hopi Lin; Michelle E Erlich; David E Moody; Jeffrey S Barrett; Walter K Kraft
Journal:  Pharmacotherapy       Date:  2015-07-14       Impact factor: 4.705

5.  Evaluation of the clearance of a sublingual buprenorphine spray in the beagle dog using gamma scintigraphy.

Authors:  Fiona McInnes; Nicola Clear; Gerry James; Howard N E Stevens; Unai Vivanco; Michael Humphrey
Journal:  Pharm Res       Date:  2007-09-01       Impact factor: 4.200

6.  Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.

Authors:  Debra S Harris; John E Mendelson; Emil T Lin; Robert A Upton; Reese T Jones
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 7.  Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.

Authors:  Hao Zhang; Jie Zhang; James B Streisand
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children.

Authors:  K T Olkkola; K Hamunen; E L Maunuksela
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

9.  Pharmacokinetic Profiles of Nalbuphine after Intraperitoneal and Subcutaneous Administration to C57BL/6 Mice.

Authors:  Brenda L Kick; Pan Shu; Bo Wen; Duxin Sun; Douglas K Taylor
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-09-01       Impact factor: 1.232

10.  Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system.

Authors:  Ram P Kapil; Alessandra Cipriano; Gregory H Michels; Peter Perrino; Sarah A O'Keefe; Manjunath S Shet; Salvatore V Colucci; Robert J Noveck; Stephen C Harris
Journal:  Clin Drug Investig       Date:  2012-09-01       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.